Myocarditis nursing: assessment, interventions, and NCLEX review

Introduction

Myocarditis is inflammation of the myocardium — the muscular wall of the heart. Unlike pericarditis, which affects the outer sac surrounding the heart, myocarditis directly damages cardiomyocytes, impairing the heart’s ability to contract and conduct electrical signals. The condition disproportionately affects young, previously healthy individuals, making it a high-stakes diagnosis nursing students must understand thoroughly.

The clinical spectrum ranges from subclinical disease (mild chest discomfort that resolves spontaneously) to fulminant myocarditis with rapid-onset cardiogenic shock requiring mechanical circulatory support. Sudden cardiac death in young athletes is one of the most feared outcomes. For nurses, early recognition, continuous cardiac monitoring, and strict activity management are the pillars of care.

Quick reference table

Pathophysiology

Myocarditis begins with a trigger — most often a viral infection — that initiates a cascade of immune-mediated myocardial injury. The process unfolds in three overlapping phases.

Acute phase (days 1–14): The pathogen directly invades cardiomyocytes, triggering innate immune activation. Natural killer cells and macrophages are recruited. In viral disease, the virus itself causes cytotoxic injury — Coxsackievirus B, for example, uses the coxsackievirus-adenovirus receptor (CAR) to enter cardiomyocytes and replicate, directly lysing cells.

Subacute phase (weeks 2–4): Adaptive immunity takes over. T-lymphocytes recognize myocardial antigens — sometimes including self-antigens due to molecular mimicry — and mount a cytotoxic attack on cardiomyocytes. This autoimmune amplification is why myocardial damage often peaks after the initial infection has cleared. Inflammatory cytokines (TNF-α, IL-1β, IL-6) suppress myocardial contractility independently of structural damage.

Chronic phase (months to years): In many patients, the immune response resolves and the myocardium recovers. In others — particularly those with extensive necrosis or ongoing autoimmune activity — progressive fibrosis and ventricular remodeling lead to dilated cardiomyopathy (DCM). Fibrotic tissue creates substrate for re-entrant arrhythmias and sudden cardiac death.

Fulminant myocarditis is a distinct, severe presentation characterized by abrupt onset (often following a clear viral prodrome), hemodynamic compromise, and paradoxically a better long-term prognosis than subacute myocarditis — provided the patient survives the acute phase with mechanical support.

The Dallas criteria define the histological diagnosis: active myocarditis requires inflammatory infiltrate with adjacent myocyte necrosis on endomyocardial biopsy. Borderline myocarditis shows infiltrate without necrosis. The diagnostic yield of biopsy is low (~20–35%) due to sampling error, which is why cardiac MRI has become the preferred non-invasive diagnostic standard.

Causes and risk factors

Etiology table

Key risk factors: Male sex (2:1 predominance), age 15–45 years, recent viral illness (1–4 weeks prior), immunosuppression, residence in or travel to Chagas-endemic areas.

Clinical presentation

Myocarditis presents along a spectrum — from incidental ECG findings after a “flu-like” illness to fulminant hemodynamic collapse. The preceding viral illness, typically 1–4 weeks before cardiac symptoms, is a critical historical detail.

Chest pain is the most common presenting complaint. It is often pleuritic (worsening with inspiration or position) when pericarditis co-exists (myopericarditis), but can also be pressure-type, mimicking acute coronary syndrome — particularly because troponin is elevated in both.

Dyspnea reflects ventricular dysfunction and reduced cardiac output. Orthopnea (dyspnea when lying flat) and paroxysmal nocturnal dyspnea indicate worsening heart failure.

Palpitations and syncope result from arrhythmias — both supraventricular and ventricular. New onset ventricular tachycardia in a young patient with a recent viral illness should immediately raise suspicion for myocarditis.

Constitutional symptoms — fever, malaise, myalgias, and fatigue — are common and reflect the underlying inflammatory process. Fatigue is often disproportionate to the degree of cardiac dysfunction, an important clinical clue.

Fulminant myocarditis presents dramatically: cardiogenic shock, rapid deterioration over hours to days, severely reduced ejection fraction, and hemodynamic instability requiring vasopressors or mechanical support. Despite its severity, fulminant myocarditis has a paradoxically better long-term prognosis than subacute forms — the intense immune response tends to resolve completely rather than progress to DCM.

The classic demographic — a young, previously healthy male presenting with chest pain and dyspnea following a respiratory or GI illness — should always trigger myocarditis on the differential, particularly if initial workup rules out ACS.

Diagnostics

Lake Louise criteria (2018 update): Cardiac MRI diagnoses myocarditis when at least one T2-based criterion (myocardial edema) AND at least one T1-based criterion (myocardial injury/fibrosis, including LGE) are present. LGE in a non-ischemic pattern (subepicardial or mid-myocardial, sparing the subendocardium) distinguishes myocarditis from infarction.

Medical management

Most patients with acute myocarditis receive supportive care; immunosuppression is reserved for specific histological subtypes.

Activity restriction is non-negotiable and is one of the most important nursing teaching points. Current AHA/EHRA guidelines recommend avoiding competitive sports and strenuous physical activity for a minimum of 3–6 months after acute myocarditis (regardless of symptom resolution) and until cardiac MRI and Holter monitoring demonstrate recovery. Premature return to exercise in the acute inflammatory phase is a recognized trigger for fatal arrhythmias and sudden cardiac death in young athletes.

Heart failure management: Once the patient is hemodynamically stable, standard HF pharmacotherapy is initiated — ACE inhibitors or ARBs (afterload reduction, myocardial remodeling prevention), beta-blockers (rate control, antiarrhythmic effect, remodeling prevention), and loop diuretics for volume overload. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) are added for LVEF ≤35%.

Avoid NSAIDs: NSAIDs are contraindicated in myocarditis. Experimental data demonstrate that NSAIDs increase viral replication in the myocardium and worsen myocardial injury in mouse models of Coxsackievirus myocarditis. This distinguishes myocarditis management from pericarditis, where NSAIDs and colchicine are first-line.

Immunosuppression:

• Giant cell myocarditis: Requires aggressive immunosuppression — typically high-dose corticosteroids combined with cyclosporine or azathioprine. Without treatment, median survival is only 5.5 months from symptom onset.
• Autoimmune / immune-mediated myocarditis (SLE, sarcoidosis): Treat the underlying condition; corticosteroids are standard.
• Checkpoint inhibitor myocarditis: Immediate cessation of the offending agent and high-dose IV methylprednisolone. Rapid escalation to mycophenolate or IVIG if refractory.
• Lymphocytic myocarditis: Routine corticosteroid use is not supported by current evidence and may worsen outcomes in active viral infection.

IVIG: Recommended for pediatric patients with acute myocarditis and hemodynamic compromise. Evidence in adults is less robust.

Mechanical circulatory support (MCS): Fulminant myocarditis with cardiogenic shock may require:

• Intra-aortic balloon pump (IABP) — reduces afterload and augments diastolic perfusion
• Impella (axial flow pump) — provides higher degree of hemodynamic support
• Veno-arterial ECMO (VA-ECMO) — for severe biventricular failure; allows cardiac rest and recovery

These patients require ICU-level nursing care. The goal is to “bridge” the patient through the acute inflammatory phase, after which the myocardium may recover substantially.

Heart transplantation: Reserved for patients with refractory, progressive disease who are not MCS candidates or do not recover on support.

Nursing assessment and interventions

Hemodynamic and cardiac monitoring

Continuous telemetry is mandatory in all patients with confirmed or suspected myocarditis. The primary nursing concern is life-threatening arrhythmia — ventricular tachycardia and ventricular fibrillation occur without warning and are the leading cause of sudden death in this population. Report any new PVCs, VT runs, heart block, or rate changes immediately to the provider.

Monitor vital signs with particular attention to:

• Heart rate: Tachycardia is common and expected with systemic inflammation and reduced stroke volume. New bradycardia suggests conduction system involvement (heart block).
• Blood pressure: Hypotension signals hemodynamic compromise; prompt escalation is required.
• SpO2: Continuous pulse oximetry; supplemental oxygen for saturation below 94%.
• Temperature: Fever elevates myocardial oxygen demand — antipyretics (acetaminophen, not NSAIDs) should be administered per order.

Fluid and volume management

Myocarditis with reduced EF carries significant risk of fluid overload and progression to acute decompensated heart failure.

• Strict intake and output monitoring every 4–8 hours (hourly for unstable patients)
• Daily weights at the same time each morning, before eating, after voiding
• Assess for JVD, peripheral edema, adventitious breath sounds (crackles), and orthopnea at each assessment
• Report weight gains of >2 lbs overnight or >5 lbs in a week immediately
• Fluid restriction may be ordered for patients with significant LV dysfunction

Activity restriction and positioning

Strict bed rest is standard in the acute inflammatory phase. Explain the rationale clearly to patients — particularly young athletes who feel “not that sick” and struggle to understand why they cannot exercise. Physical activity during active myocardial inflammation dramatically increases arrhythmia risk and can precipitate sudden cardiac death.

• Elevate the head of bed to 30–45 degrees for orthopnea and to reduce preload
• Assist with all activities of daily living during the acute phase
• Implement a graduated activity protocol only after provider authorization and documented hemodynamic stability

Pain and symptom management

Chest pain should be assessed with each set of vital signs. Use a standardized scale (0–10 NRS). Differentiate between pleuritic chest pain (pericarditis component) and pressure-type chest pain (myocardial ischemia) — report changes in character or severity. Acetaminophen is the analgesic of choice; NSAIDs are contraindicated.

Medication monitoring

• Beta-blockers: Monitor for symptomatic bradycardia and hypotension before each dose; hold for HR <50 bpm or SBP <90 mmHg per protocol.
• ACE inhibitors/ARBs: Monitor renal function and potassium; watch for first-dose hypotension.
• Diuretics: Monitor electrolytes — hypokalemia increases arrhythmia risk.
• Anticoagulation: Patients with severely reduced EF (<35%) or documented intracardiac thrombus may be anticoagulated; monitor for bleeding.

Patient and family education

• Activity restriction is the most critical teaching point. No competitive sports, heavy lifting, or vigorous exercise for the full prescribed period (minimum 3–6 months).
• Return precautions: chest pain, palpitations, syncope, worsening dyspnea, or leg swelling — return to ED immediately.
• Importance of follow-up cardiac MRI and Holter monitoring before return to exercise.
• Medication adherence — especially beta-blockers and ACE inhibitors, which must not be stopped abruptly.
• Alcohol avoidance — alcohol is cardiotoxic and can worsen LV dysfunction.

Complications

Risk stratification for SCD: Patients with any of the following warrant consideration of ICD implantation or close follow-up: LVEF <50% at 3–6 months despite optimal medical therapy, extensive LGE on cardiac MRI, non-sustained VT on ambulatory monitoring, or prior resuscitated cardiac arrest.

Myocarditis vs pericarditis

These conditions share features — chest pain, ECG changes, elevated inflammatory markers, young patient demographics — but differ in important ways that affect management.

When both layers are involved, the term myopericarditis is used — myocardial involvement is dominant. Perimyocarditis implies pericarditis is the dominant process with minor myocardial involvement. The distinction matters for management decisions.

See the full comparison in the pericarditis nursing reference.

NCLEX tips

• Coxsackievirus B is the most common cause of viral myocarditis — the single most tested fact about myocarditis etiology.
• NSAIDs are contraindicated in myocarditis — this is the reverse of pericarditis, where NSAIDs are first-line. NCLEX loves this distinction.
• Activity restriction for 3–6 months minimum — the AHA/EHRA guideline period before return to competitive sports. Patients who “feel better” are not cleared to exercise without cardiac imaging follow-up.
• Giant cell myocarditis has the worst prognosis of all subtypes — rapidly fatal without immunosuppression; median survival under 6 months if untreated.
• Cardiac MRI with late gadolinium enhancement (LGE) is the gold-standard non-invasive diagnostic test. LGE in a subepicardial or mid-myocardial pattern (not subendocardial) differentiates myocarditis from myocardial infarction.
• Troponin is elevated in myocarditis — this differentiates it from pure pericarditis. Elevated troponin in a young patient with chest pain and recent viral illness = think myocarditis.
• Fulminant myocarditis presents with rapid cardiogenic shock but paradoxically has a better long-term prognosis than subacute myocarditis.
• VA-ECMO or Impella may be required for fulminant myocarditis with cardiogenic shock — mechanical support is a bridge to recovery.
• Young athlete + chest pain + viral prodrome 1–4 weeks prior = classic myocarditis presentation. Know this clinical picture.
• Telemetry is mandatory — VT and VF occur without warning; continuous monitoring is a nursing priority.
• Avoid NSAIDs — they increase viral replication and worsen myocardial injury in viral myocarditis.
• IVIG is recommended for pediatric acute myocarditis — less evidence in adults.
• Checkpoint inhibitor myocarditis (from cancer immunotherapy drugs like pembrolizumab) is rare but rapidly fatal — stop the drug immediately and give high-dose corticosteroids.
• Chagas disease (Trypanosoma cruzi) is a major cause of myocarditis and DCM in Latin America — important for NCLEX questions with travel history or immigrant populations.
• Daily weights — weight gain of >2 lbs overnight signals fluid retention and worsening heart failure; report immediately.

Internal links

• Heart failure nursing: assessment, interventions, and NCLEX review — myocarditis frequently progresses to acute decompensated heart failure; review HF management in parallel
• Pericarditis nursing: assessment, interventions, and NCLEX review — often co-exists with myocarditis as myopericarditis; key comparison for NCLEX
• Infective endocarditis nursing: assessment, interventions, and NCLEX review — another infectious cardiac condition with overlapping inflammatory mechanisms
• Atrial fibrillation nursing: assessment, interventions, and NCLEX review — myocarditis-associated atrial arrhythmias and rate control management
• EKG interpretation cheat sheet for nurses — interpreting the ST changes, T-wave inversions, and arrhythmias associated with myocarditis
• Sepsis nursing: assessment, interventions, and NCLEX review — fulminant myocarditis with cardiogenic shock shares hemodynamic monitoring priorities with septic shock